Paragon Global CRS BV

08/12/2021

The road to and through a clinical trial.

Developing a new cancer drug takes years of research, millions of substances to examine, and billions of Euros. Take an in-depth look at the drug creation pr...

21/06/2021

17/12/2020

25/09/2020

We are moving!

We are relocating our European office! October 1, 2020, the Paragon Global CRS, EU office will move to Barendrecht. Our EU mailing address has also been...

11/09/2020

Finally time to celebrate our mutual birthday. (September 2nd 19..)

16/06/2020

Dinner with the IT team from Milan. New CRS portal is almost ready!

24/03/2020

Paragon Home Office

14/03/2020

With the Coronavirus COVID-19 health emergency, we have been contacted by several customers who are updating their business continuity plans and seeking information on how Paragon Global CRS will manage its global operations during this challenging time.

Paragon Global CRS has taken measures to provide our customers with the high level of service they have come to expect even though the world is experiencing the COVID-19 pandemic/health emergency.

Be assured that we have provided training and counsel to our team members to help them to prevent illness for themselves and their families and to prepare them for the possible effects of quarantine.

Over the last several weeks, Paragon Global CRS management has continuously reviewed and updated our COVID-19 Preparedness Plan to ensure that we can readily support and replace, if necessary, any incapacitated support staff. In both the US and EU Paragon Global CRS offices, remote support staff have been and continue to be in place to support operations. Since we are a global operation, many associates already work from remote locations. Thus, we have implemented plans to have them to continue working remotely to limit their contact with those who might pose a health threat. We are urging all of our associate to act responsibly when it comes to contact with business associates, friends, and family members to prevent the spread of COVID-19 and other pathogens. Also, since Paragon Global CRS is a cloud-based operation with team members spread around the globe, the risk of our being unable to provide the level of service our customers appreciate is minimal. Travel restrictions and local area quarantines will have no impact on our global workforce.

Paragon Global CRS anticipates little business continuity impact and will continue providing service to our customers with the same high level of efficiency and thoroughness they have come to expect.

Our entire EU office has been on remote working restriction effective March 9th. Our US operations have already implemented a scaled remote working restriction and will continue to monitor the situation and respond as necessary.

The health and well-being of our many associates, clients and their employees, and the study subjects with whom we interact are of the utmost importance to us at Paragon Global CRS.

If you have any questions or concerns, please contact

Drew Massey
Vice-President
Paragon Global CRS
5725 Oleander Drive D-4
Wilmington, NC 28403
O 888-429-5875
C 910-620-6004

René M. Buijse
EU Operations Director
Paragon Global CRS
Marten Meesweg 8-10
3068 AV Rotterdam
The Netherlands
O +31-10 2004220
C +31-611 844 614

21/01/2020

After 6 months probation, Marjolein signed her permanent contract as Office/Project Manager at Paragon Global CRS. Glad to have you on board! Cheers!!!!

02/01/2020

https://www.euronews.com/2020/01/02/lottery-for-babies-lives-drugmaker-launches-lucky-draw-for-life-saving-gene-therapy

Swiss drugmaker Novartis has launched an international lottery for its groundbreaking and extremely costly gene therapy Zolgensma, sparking both hope and outrage among patients’ families.

02/01/2020

In de clinical trial verbonden aan deze gene therapy hebben we 31 babies en hun family ondersteund en begeleid. Alle babies hebben intussen hun 1ste verjaardag al maanden geleden gevierd. Alle babies hadden een levens verwachting van 3 to 6 maanden.

In the clinical trial that is connected to this gene therapy we have supported 31 babies in the EU. All of them celebrated their 1st birthday months ago. All of them had a life expectancy of 3 to 6 months.

Nog geen twee maanden nadat baby Pia uit België haar levensreddende prik kreeg toegediend, gaat haar gezondheid er steeds meer op vooruit. Het meisje kan rollen, grijpt met haar handjes, en brabbelt er op los. Haar ouders spraken ondertussen ook met de producent van het peperdure geneesmiddel Zolge...

26/11/2019

Vele malen per week wordt mij gevraagd wat Paragon Global CRS nou voor bedrijf is. Rene, wat doen jullie nou eigenlijk? Aangezien de naam Paragon redelijk generiek is en CRS voor van alles kan staan, lijkt het me zinvol wat meer tekst en uitleg te geven.

26/11/2019

AMT-061 is currently being studied in the Phase III HOPE-B Pivotal Study in Patients with Hemophilia B.

Paragon services: Travel support national and international (flights, ground, hotels), Reimbursement. Belgium, Netherlands, France, Italy, Germany, Sweden, UK, Ireland, South Africa, Canada and the US.

AMT-061 is an investigational gene therapy being studied in clinical trials by uniQure in the HOPE-B (Health Outcomes with Padua gene; Evaluation in Hemophilia-B) trial for adults with moderately severe or severe hemophilia.  The goal of treatment with AMT-061 is to help the liver produce Factor I...

26/11/2019

One of the most intense studies we have ever worked on. Relocation and support of families with 2 months old infants from all over the world to hospitals in Milan, Rome, Genova, Paris, Liege, London and support them for 16 months with housing, reimbursement, ground transport, flights and moral support. Babies with a life expectancy of max 7 months who all celebrated their 1 birthday 😃

Read about Zolgensma (AVXS-101), an SMA gene therapy by AveXis designed to cross the blood-brain barrier and address the genetic causes of the disease.

26/11/2019

Studies we handle in some way or form. In this case: Reimbursement specialist.

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study - Full Text View.

21/10/2019

Today the first patient in this trial arrives in Amsterdam. Paragon Global CRS coordinates all patient travel in the EU for this Hope-B study.

uniQure is advancing a promising clinical program focused on hemophilia B, a severe orphan blood clotting disorder. Our gene therapy product candidate etranacogene dezaparvovec (AMT-061) consists of an AAV5 viral vector carrying a gene cassette with the Padua variant of Factor IX (FIX-Padua). 

20/09/2019

20/09/2019

De ouders van de negen maanden oude Vlaamse baby Pia Boehnke kunnen het bijna niet geloven. Duizenden Belgen hebben zich de afgelopen dagen met succes ingezet om geld in te zamelen voor het meisje, dat lijdt aan de spierziekte SMA Type 1. Hulp was hard nodig: er is slechts één medicijn dat haar ka...